Signatures of copy number alterations in human cancer.

Aneuploidy Chromothripsis DNA Copy Number Variations / genetics DNA Mutational Analysis Haploidy Homologous Recombination / genetics Humans Loss of Heterozygosity / genetics Mutation Neoplasms / genetics Exome Sequencing

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
06 2022
Historique:
received: 26 04 2021
accepted: 07 04 2022
pubmed: 16 6 2022
medline: 2 7 2022
entrez: 15 6 2022
Statut: ppublish

Résumé

Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-related processes of replication stress, mitotic errors, spindle multipolarity and breakage-fusion-bridge cycles, among others, which may lead to chromosomal instability and aneuploidy

Identifiants

DOI: 10.1038/s41586-022-04738-6 PMID: 35705804 PMC: PMC9242861
pubmed: 35705804
doi: 10.1038/s41586-022-04738-6
pii: 10.1038/s41586-022-04738-6
pmc: PMC9242861
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

984-991

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001202
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : R01 ES030993
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES032547
Pays : United States
Organisme : Medical Research Council
ID : MR/L016311/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : FC001202
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Sansregret, L. & Swanton, C. The role of aneuploidy in cancer evolution. Cold Spring Harb. Perspect. Med. 7, a028373 (2017).
pubmed: 28049655 pmcid: 5204330 doi: 10.1101/cshperspect.a028373
Levine, M. S. & Holland, A. J. The impact of mitotic errors on cell proliferation and tumorigenesis. Genes Dev. 32, 620–638 (2018).
pubmed: 29802124 pmcid: 6004076 doi: 10.1101/gad.314351.118
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
pubmed: 20164920 pmcid: 2826709 doi: 10.1038/nature08822
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).
pubmed: 28104840 pmcid: 5592794 doi: 10.1126/science.aaf8399
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689.e3 (2018).
pubmed: 29622463 pmcid: 6028190 doi: 10.1016/j.ccell.2018.03.007
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
pubmed: 29625048 pmcid: 5957518 doi: 10.1016/j.cell.2018.03.022
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179 pmcid: 6072608 doi: 10.1038/s41588-018-0165-1
Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
pubmed: 21215367 pmcid: 3065307 doi: 10.1016/j.cell.2010.11.055
Bolhaqueiro, A. C. F. et al. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nat. Genet. 51, 824–834 (2019).
pubmed: 31036964 doi: 10.1038/s41588-019-0399-6
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 3776390 doi: 10.1038/nature12477
Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat. Rev. Cancer 21, 619–637 (2021).
pubmed: 34316057 doi: 10.1038/s41568-021-00377-7
Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).
pubmed: 32025012 pmcid: 7025897 doi: 10.1038/s41586-019-1913-9
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866 doi: 10.1038/nature17676
Thutkawkorapin, J., Eisfeldt, J., Tham, E. & Nilsson, D. pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing. BMC Bioinformatics 21, 128 (2020).
pubmed: 32245405 pmcid: 7118897 doi: 10.1186/s12859-020-3451-8
Steele, C. D. et al. Undifferentiated sarcomas develop through distinct evolutionary pathways. Cancer Cell 35, 441–456.e8 (2019).
pubmed: 30889380 pmcid: 6428691 doi: 10.1016/j.ccell.2019.02.002
Maclachlan, K. H. et al. Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nat. Commun. 12, 5172 (2021).
pubmed: 34453055 pmcid: 8397708 doi: 10.1038/s41467-021-25469-8
Macintyre, G. et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat. Genet. 50, 1262–1270 (2018).
pubmed: 30104763 pmcid: 6130818 doi: 10.1038/s41588-018-0179-8
Pladsen, A. V. et al. Copy number motifs expose genome instability type and predict driver events and disease outcome in breast cancer. Preprint at bioRxiv https://doi.org/10.1101/769356 (2019).
Wang, S. et al. Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes. PLoS Genet. 17, e1009557 (2021).
pubmed: 33945534 pmcid: 8121287 doi: 10.1371/journal.pgen.1009557
Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Preprint at bioRxiv https://doi.org/10.1101/2020.12.13.422570 (2021).
Lopez, S. et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat. Genet. 52, 283–293 (2020).
pubmed: 32139907 pmcid: 7116784 doi: 10.1038/s41588-020-0584-7
Tarabichi, M. et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat. Methods 18, 144–155 (2021).
pubmed: 33398189 pmcid: 7867630 doi: 10.1038/s41592-020-01013-2
Davoli, T. et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948–962 (2013).
pubmed: 24183448 pmcid: 3891052 doi: 10.1016/j.cell.2013.10.011
Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891–897 (2020).
pubmed: 32807987 pmcid: 7484012 doi: 10.1038/s41588-020-0678-2
Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).
pubmed: 23446422 pmcid: 4636055 doi: 10.1038/nature11935
Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29, 723–736 (2016). 
pubmed: 27165744 pmcid: 4864952 doi: 10.1016/j.ccell.2016.04.002
Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330 (2014).
pubmed: 25155756 pmcid: 4160352 doi: 10.1016/j.ccr.2014.07.014
Menghi, F. et al. The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell 34, 197–210.e5 (2018).
pubmed: 30017478 pmcid: 6481635 doi: 10.1016/j.ccell.2018.06.008
Deshpande, V. et al. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat. Commun. 10, 392 (2019).
pubmed: 30674876 pmcid: 6344493 doi: 10.1038/s41467-018-08200-y
Hadi, K. et al. Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs. Cell 183, 197–210.e32 (2020).
pubmed: 33007263 pmcid: 7912537 doi: 10.1016/j.cell.2020.08.006
Lo, A. W. et al. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. Neoplasia 4, 531–538 (2002).
pubmed: 12407447 pmcid: 1503667 doi: 10.1038/sj.neo.7900267
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Cortes-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331–341 (2020).
pubmed: 32025003 pmcid: 7058534 doi: 10.1038/s41588-019-0576-7
Knudson, A. G. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122, 135–140 (1996).
pubmed: 8601560 doi: 10.1007/BF01366952
Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242–252 (2013).
pubmed: 23334668 pmcid: 3919793 doi: 10.1038/ng.2532
Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 3698 (2018).
pubmed: 29925010 doi: 10.1016/j.celrep.2018.06.032
Scarpa, A. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543, 65–71 (2017).
pubmed: 28199314 doi: 10.1038/nature21063
Nichols, C. A. et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat. Commun. 11, 2517 (2020).
pubmed: 32433464 pmcid: 7239950 doi: 10.1038/s41467-020-16399-y
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041.e21 (2017).
pubmed: 29056346 pmcid: 5720395 doi: 10.1016/j.cell.2017.09.042
Van den Eynden, J., Basu, S. & Larsson, E. Somatic mutation patterns in hemizygous genomic regions unveil purifying selection during tumor evolution. PLoS Genet. 12, e1006506 (2016).
pubmed: 28027311 pmcid: 5189942 doi: 10.1371/journal.pgen.1006506
McBride, D. J. et al. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J. Pathol. 227, 446–455 (2012).
pubmed: 22514011 pmcid: 3428857 doi: 10.1002/path.4042
Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92, 564–569 (2000).
pubmed: 10749912 doi: 10.1093/jnci/92.7.564
Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 4, 16 (2018).
pubmed: 29978035 pmcid: 6028448 doi: 10.1038/s41523-018-0066-6
Sakofsky, C. J. et al. Repair of multiple simultaneous double-strand breaks causes bursts of genome-wide clustered hypermutation. PLoS Biol. 17, e3000464 (2019).
pubmed: 31568516 pmcid: 6786661 doi: 10.1371/journal.pbio.3000464
Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965.e28 (2017).
doi: 10.1016/j.cell.2017.10.014
Bindra, R. S. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol. 24, 8504–8518 (2004).
pubmed: 15367671 pmcid: 516750 doi: 10.1128/MCB.24.19.8504-8518.2004
Chan, N. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605–614 (2008).
pubmed: 18199558 doi: 10.1158/0008-5472.CAN-07-5472
Bhandari, V. et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 51, 308–318 (2019).
pubmed: 30643250 doi: 10.1038/s41588-018-0318-2
Thorsson, V. et al. The immune landscape of cancer. Immunity 51, 411–412 (2019).
pubmed: 31433971 doi: 10.1016/j.immuni.2019.08.004
Overgaard, J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother. Oncol. 100, 22–32 (2011).
pubmed: 21511351 doi: 10.1016/j.radonc.2011.03.004
Sinha, S. et al. Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European Americans. Nat. Cancer 1, 112–121 (2020).
pubmed: 35121843 pmcid: 8921973 doi: 10.1038/s43018-019-0009-7
de Jonge, M. M. et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin. Cancer Res. 25, 1087–1097 (2019).
pubmed: 30413523 doi: 10.1158/1078-0432.CCR-18-1443
Abbasi, A. & Alexandrov, L. B. Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures. DNA Repair (Amst.) 107, 103200 (2021).
doi: 10.1016/j.dnarep.2021.103200
Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).
pubmed: 28288110 pmcid: 5833945 doi: 10.1038/nm.4292
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
pubmed: 20837533 pmcid: 2947907 doi: 10.1073/pnas.1009843107
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
pubmed: 22544022 pmcid: 4383288 doi: 10.1038/nbt.2203
Sandve, G. K., Ferkingstad, E. & Nygard, S. Sequential Monte Carlo multiple testing. Bioinformatics 27, 3235–3241 (2011).
pubmed: 21998154 pmcid: 3223366 doi: 10.1093/bioinformatics/btr568
Liu, J. et al. An integrated TCGA pan-cancer clinical data Resource to drive high-quality survival outcome analytics. Cell 173, 400–416.e11 (2018).
pubmed: 29625055 pmcid: 6066282 doi: 10.1016/j.cell.2018.02.052
Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354, 618–622 (2016).
pubmed: 27811275 pmcid: 6141049 doi: 10.1126/science.aag0299
Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109–1112 (2016).
pubmed: 27653561 pmcid: 6309165 doi: 10.1056/NEJMp1607591
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage tepair deficiency across The Cancer Genome Atlas. Cell Rep. 23, 239–254.e6 (2018).
pubmed: 29617664 pmcid: 5961503 doi: 10.1016/j.celrep.2018.03.076
Nguyen, L., Martens, W. M., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).
pubmed: 33149131 pmcid: 7643118 doi: 10.1038/s41467-020-19406-4
Yost, S., Ruark, E., Alexandrov, L. B. & Rahman, N. Insights into BRCA cancer predisposition from integrated germline and somatic analyses in 7632 cancers. JNCI Cancer Spectr. 3, pkz028 (2019).
pubmed: 31360904 pmcid: 6649772 doi: 10.1093/jncics/pkz028
Takaya, H., Nakai, H., Takamatsu, S., Mandai, M. & Matsumura, N. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 10, 2757 (2020).
pubmed: 32066851 pmcid: 7026096 doi: 10.1038/s41598-020-59671-3
Eustace, A. et al. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin. Cancer Res. 19, 4879–4888 (2013).
pubmed: 23820108 pmcid: 3797516 doi: 10.1158/1078-0432.CCR-13-0542
Lechner, M. et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV
pubmed: 23718828 pmcid: 4064312 doi: 10.1186/gm453
Mardin, B. R. et al. A cell-based model system links chromothripsis with hyperploidy. Mol. Syst. Biol. 11, 828 (2015).
pubmed: 26415501 pmcid: 4592670 doi: 10.15252/msb.20156505
Nilsen, G. et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
pubmed: 23442169 pmcid: 3582591 doi: 10.1186/1471-2164-13-591
Browning, B. L., Zhou, Y. & Browning, S. R. A one-penny imputed genome from next-generation reference panels. Am. J. Hum. Genet. 103, 338–348 (2018).
pubmed: 30100085 pmcid: 6128308 doi: 10.1016/j.ajhg.2018.07.015
Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
pubmed: 22608083 pmcid: 3428864 doi: 10.1016/j.cell.2012.04.023
Behjati, S. et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat. Commun. 8, 15936 (2017).
pubmed: 28643781 pmcid: 5490007 doi: 10.1038/ncomms15936
Pinto, E. M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 6302 (2015).
pubmed: 25743702 doi: 10.1038/ncomms7302

Auteurs

Christopher D Steele (CD)

Research Department of Pathology, Cancer Institute, University College London, London, UK.

Ammal Abbasi (A)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

S M Ashiqul Islam (SMA)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

Amy L Bowes (AL)

Research Department of Pathology, Cancer Institute, University College London, London, UK.
Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.

Azhar Khandekar (A)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA.

Kerstin Haase (K)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
ORCID: 0000-0002-0944-5618

Shadi Hames-Fathi (S)

Research Department of Pathology, Cancer Institute, University College London, London, UK.

Dolapo Ajayi (D)

Research Department of Pathology, Cancer Institute, University College London, London, UK.

Annelien Verfaillie (A)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.

Pawan Dhami (P)

CRUK-UCL Cancer Institute Translational Technology Platform (Genomics), London, UK.

Alex McLatchie (A)

CRUK-UCL Cancer Institute Translational Technology Platform (Genomics), London, UK.

Matt Lechner (M)

Research Department of Oncology, UCL Cancer Institute, London, UK.
ORCID: 0000-0002-7123-0773

Nicholas Light (N)

Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Adam Shlien (A)

Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID: 0000-0002-0368-5370

David Malkin (D)

Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
ORCID: 0000-0001-5752-9763

Andrew Feber (A)

Translational Epigenetics, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
Clinical Genomics, Translational Research Laboratory, Royal Marsden NHS Trust, London, UK.

Paula Proszek (P)

Translational Epigenetics, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
Clinical Genomics, Translational Research Laboratory, Royal Marsden NHS Trust, London, UK.
ORCID: 0000-0002-0780-6790

Tom Lesluyes (T)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
ORCID: 0000-0003-2251-5884

Fredrik Mertens (F)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Clinical Genetics and Pathology, Division of Laboratory Medicine, Lund, Sweden.
ORCID: 0000-0002-6278-5232

Adrienne M Flanagan (AM)

Research Department of Pathology, Cancer Institute, University College London, London, UK.
Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK.
ORCID: 0000-0002-2832-1303

Maxime Tarabichi (M)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Institute for Interdisciplinary Research, Université Libre de Bruxelles, Brussels, Belgium.
ORCID: 0000-0002-1635-2348

Peter Van Loo (P)

Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
ORCID: 0000-0003-0292-1949

Ludmil B Alexandrov (LB)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA. L2alexandrov@health.ucsd.edu.
Department of Bioengineering, UC San Diego, La Jolla, CA, USA. L2alexandrov@health.ucsd.edu.
Moores Cancer Center, UC San Diego, La Jolla, CA, USA. L2alexandrov@health.ucsd.edu.

Nischalan Pillay (N)

Research Department of Pathology, Cancer Institute, University College London, London, UK. N.pillay@ucl.ac.uk.
Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. N.pillay@ucl.ac.uk.
ORCID: 0000-0003-0579-4105

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Ploïdies › Aneuploïdie › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Aberrations des chromosomes › Chromothripsis › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Variation structurale du génome › Variations de nombre de copies de segment d'ADN › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Analyse de mutations d'ADN › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Ploïdies › Haploïdie › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Recombinaison génétique › Recombinaison homologue › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Déséquilibre allélique › Perte d'hétérozygotie › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Tumeurs › Signatures of copy number alterations in human cancer.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Séquençage du génome entier › Séquençage de l'exome › Signatures of copy number alterations in human cancer.